A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

NCT01900652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Emibetuzumab
DRUG: Erlotinib

Sponsor

Eli Lilly and Company